Table 2.
Survival Differences Based on HFE Group, MGMT Status, Sex, and Temozolomide Therapy
| All Data | Low HFE mRNA (<Median) | High HFE mRNA (≥Median) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Deaths | Median (CI) | P | N | Deaths | Median (CI) | P | N | Deaths | Median (CI) | P | ||
| Sex | Male | 283 | 242 | 12.7 (11.9–14.0) | 142 | 120 | 12.6 (10.9–13.9) | 141 | 122 | 12.9 (11.9–14.9) | |||
| Female | 177 | 142 | 12.5 (10.5–15.3) | 78 | 62 | 14.7 (11.5–20.1) | 99 | 80 | 10.7 (8.6–14.9) | ||||
| Log rank | .8 | .07 | .1 | ||||||||||
| CoxPHa | .049* | .003** | .7 | ||||||||||
| MGMT | Methylated | 128 | 100 | 15.3 (12.9–17.8) | 66 | 54 | 16.9 (13.8–21.2) | 62 | 46 | 13.6 (10.7–18.1) | |||
| Unmethylated | 173 | 132 | 12.2 (10.7–14.0) | 85 | 66 | 11.5 (10.1–13.3) | 88 | 66 | 12.9 (10.8–14.9) | ||||
| Log rank | .002** | .002** | .4 | ||||||||||
| CoxPHa | .12 | .014* | .6 | ||||||||||
| Sex and MGMT (All therapy) | Male: Methylated | 66 | 55 | 13.3 (10.7–17.6) | 40 | 35 | 13.3 (10.2–19.5) | 26 | 20 | 12.9 (7.6–20.4) | |||
| Female: Methylated | 62 | 45 | 17.8 (13.8–21.3) | 26 | 19 | 24.9 (17.8–33.2) | 36 | 26 | 13.6 (7.0–20.7) | ||||
| Male: Unmethylated | 112 | 87 | 12.6 (10.6–14.0) | 57 | 45 | 10.9 (9.5–14.0) | 55 | 42 | 12.9 (11.9–15.0) | ||||
| Female: Unmethylated | 61 | 45 | 11.7 (9.9–17.5) | 28 | 21 | 11.7 (9.9–22.2) | 33 | 24 | 12.2 (8.8–17.9) | ||||
| Log rank | .001** | <.0001**** | .7 | ||||||||||
| CoxPHb | .002** | <.0001**** | .3 | ||||||||||
| Temozolomide Therapy | Male: Methylated | 47 | 38 | 16.5 (13.3–20.8) | 31 | 26 | 16.1 (12.7–21.1) | 16 | 12 | 18.1 (12.9-NA) | |||
| Female: Methylated | 43 | 28 | 20.7 (15.6–26.9) | 19 | 14 | 25.7 (19.9-NA) | 24 | 14 | 15.6 (12.4-NA) | ||||
| Male: Unmethylated | 81 | 60 | 12.9 (12.2–14.9) | 40 | 31 | 12.7 (11.3–15.4) | 41 | 29 | 13.9 (12.6–16.6) | ||||
| Female: Unmethylated | 38 | 27 | 14.5 (10.2–21.9) | 18 | 13 | 11.7 (9.9-NA) | 19 | 14 | 14.9 (12.2-NA) | ||||
| Log rank | .0002*** | <.0001**** | .2 | ||||||||||
| CoxPHb | .0008*** | .0002*** | .6 | ||||||||||
| No Temozolomide Therapy | Male: Methylated | 18 | 17 | 3.1 (2.0–7.6) | 9 | 9 | 2.0 (1.1-NA) | 9 | 8 | 5.9 (2.8-NA) | |||
| Female: Methylated | 15 | 14 | 6.6 (3.6–25.4) | 5 | 4 | 15.1 (3.6-NA) | 10 | 10 | 5.5 (2.3-NA) | ||||
| Male: Unmethylated | 27 | 23 | 5.8 (1.6–10.6) | 16 | 13 | 7.6 (1.1-NA) | 11 | 10 | 5.3 (1.6-NA) | ||||
| Female: Unmethylated | 20 | 16 | 6.6 (4.6–17.5) | 8 | 7 | 6.1 (4.1-NA) | 12 | 9 | 9.1 (2.9-NA) | ||||
| Log rank | .06 | .05 | .7 | ||||||||||
| CoxPHb | .06 | .03* | .8 | ||||||||||
NA, upper confidence interval could not be calculated/infinity.
aCoxPH P-value based on hazard coefficients.
bRobustified CoxPH P-value for the overall model fit.
*P-value < .05, **P-value < .01, ***P-value < .001, ****P-value < .0001.